Introduction The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren’s disease (SjD) can be suspected from the results of two phase II clinical trials but has not been ...

Kidney inflammation caused by SLE is referred to as lupus nephritis ... becoming the first oral alternative to GSK's injectable anti-BLyS/BAFF antibody Benlysta (belimumab) for the treatment ...

Blood DC antigen 2 (BDCA2) is exclusively expressed on pDCs and its antibody BIIB059 has demonstrated preliminary efficacy and excellent safety in patients with SLE or cutaneous lupus erythematosus ...

The two drugs have overlapping indications for SLE patients, and the choice of which drug to use is mainly based on the ... First, this is based on a medical records review study. Second, continuous ...

Cyrus Biotechnology Inc. has selected CYR-212, an engineered next-generation reduced-immunogenicity and half-life extended immunoglobulin G (IgG) protease, as a clinical development candidate for ...

Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

There are so many different 5-letter words with SLE in them in the English language that might be an answer to a word puzzle or game, and sometimes we need some help narrowing down the options. If you ...

在SLE的新药研究方面，首个人源化CD40L单抗Dapirolizumab pegol的Ⅲ期临床 ... 选择性BTK抑制剂Remibrutinib通过抑制B细胞信号通路，显著减少炎症反应并改善生活质量。BAFF-R单克隆抗体Ianalumab的52周研究表明，该药物显著降低了患者的ESSDAI评分，并改善腺体功能。